This open access book, published under a CC BY 4.0 license in the Pubmed indexed book series Handbook of Experimental Pharmacology, provides up-to-date information on best practice to improve experimental design and quality of research in non-clinical pharmacology and biomedicine.

This open access book summarizes the latest scientific findings regarding the biological effects of the Fukushima Daiichi Nuclear Power Plant (FNPP) accident in 2011. Various cases of changes in animals and organisms have been reported since the FNPP accident. However, it is often unknown whether they are actually due to radiation, since the dose or dose-rate are not necessarily associated with the changes observed. This book brings together the works of radiation biologists and ecologists to provide reliable radioecology data and gives insight into future radioprotection. The book examines the environmental pollution and radiation exposure, and contains valuable data from abandoned livestock in the ex-evacuation zone and from wild animals including invertebrates and vertebrates, aqueous and terrestrial animals, and plants that are subjected to long-term exposure in the area still affected by radiation. It also analyzes dose evaluation, and offers new perspectives gained from the accident, as well as an overview for future studies to promote radioprotection of humans and the ecosystem. Since the biological impact of radiation is influenced by various factors, it is difficult to scientifically define the effects of low-dose/low-dose-rate radiation. However, the detailed research data presented can be combined with the latest scientific and technological advances, such as artificial intelligence, to provide new insights in the future. This book is a unique and valuable resource for researchers, professionals and anyone interested in the impact of exposure to radiation or contamination with radioactive materials.

This Open Access biography chronicles the life and achievements of the Norwegian engineer and physicist Rolf Wideroe. Readers who meet him in the pages of this book will wonder why he isn't better known. The first of Wideroe's many pioneering contributions in the field of accelerator physics was the betatron, the second, the linear accelerator, both summarized in a 27 page PhD. The betatron revolutionized the fields of cancer treatment through radiation therapy and also nondestructive testing; hospitals worldwide installed Wideroe's machine and today's modern radiation treatment equipment is based on his inventions. The most recent renaissance of the linac provides unprecedented x-ray intensities at Free Electron Laser (FEL) facilities in operation and construction worldwide. . Wideroe's story also includes a fair share of drama, particularly during World War II when both Germans and the Allies vied for his collaboration. Wideroe held leading positions in multinational industry groups and was one of the consultants for building the world's largest nuclear laboratory, CERN, in Switzerland. He gained over 200 patents, received several honorary doctorates and a number of international awards. The author, a professional writer and maker of TV documentaries, has gained access to hitherto restricted archives in several countries, which provided a wealth of new material and insights, in particular in relation to the war years. She tells here a gripping and illuminating story.

This book describes, in detail, tested techniques for the produc-tion and use of monoclonal antibodies. It covers those aspects of interest to all scientists working with monoclonal antibodies and presents methods in a step-by-step format for easy refer-ence. The text serves as a laboratory manual; and discusses rationale behind each method, and the choices between methods. It also provides a rational basis where several alternative methods are available.

This book highlights the wide applications of nanomaterials in healthcare and environmental remediation. Presenting nano-based materials that positively influence the growth and proliferation of cells present in soft and hard tissue and are used for the regeneration bone tissue and/or suppression of cancer cells, it also discusses the natural products that can be incorporated in nanofibers for the treatment of cancer. Further, it describes the use of blending and functionalization to produce chitosan nanofibers for biomedical applications, and reviews the role of plasma-enhanced gold nanoparticles in diagnostics and therapeutics. Lastly, the book also introduces various nanotechnology approaches for the removal of waste metabolites in drinking water, and explores the emerging applications of nanorobotics in medicine. Given its scope, this book is a valuable resource for scientists, clinicians, engineers and researchers aiming to gain a better understanding of the various applications of nanotechnology.

Advances in Cancer Research, Volume 148, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.

Revealing essential roles of the tumor microenvironment in cancer progression, this volume focuses on the extracellular matrix components of the tumor microenvironment during cancer development. Furthermore, it teaches readers about the roles of distinct constituents of the tumor microenvironment and how they affect cancer development. Topics include elastin, decorin, syndecan-1, versican, lipoproteins, brevican, thrombospondin, and much more. Taken alongside its companion volumes, Tumor Microenvironment: Extracellular Matrix Components - Part B updates us on what we know about the different aspects of the tumor microenvironment, as well as apprises us on the future advances in the field. For the newest generation of researchers, this volume serves as a useful introduction to the history of scientists' focus on the tumor microenvironment, and explores how this knowledge is currently applied in cancer treatments. The book is an essential text for advanced cell biology and cancer biology students, as well as for scientists seeking an update on the developments in tumor microenvironment research. All of the chapters authors are renowned international experts in the field of cancer biology, and in the specific subfields that are the focus of their chapters.

This book sheds new light on "inducible" lymphoid organs (ILOs): antigen presentation sites that are generated de novo in peripheral tissues under various pathogenic conditions. Accomplished immunologists demonstrate that the physiological role of these ILOs is completely different from that of central lymphoid organs, i.e., the lymph nodes or spleen. In addition to the central organs, the ILOs are considered essential structures for the efficient elicitation of adaptive immune responses in lesions. The respective chapters highlight examples from multiple sites, e.g. the skin, lung, intestinal tract, genital tract, the synovial membrane of the joints and artificial lymph nodes. Accordingly, readers will learn that ILO structure and function can vary substantially, depending on the context. Presenting the results of the latest immunological research, the book offers a fascinating and insightful read for both scientists and clinicians in the areas of infectious and immune-associated diseases.

This book, written by key researchers in the field, provides a comprehensive analysis and overview of the state of the art of plasma-based cancer therapy. Recent progress in atmospheric plasmas has led to non-thermal or cold atmospheric plasma (CAP) devices with ion temperatures close to room temperature. In contrast to many existing anti-cancer approaches, CAP is a selective anti-cancer modality which has demonstrated significant potential in cancer therapy.Written by a global, cross-disciplinary group of leading researchers, this book covers basic theory, generation, diagnostics, and simulation of cold atmospheric plasma, as well as their clinical application in cancer therapy, immunotherapy, and future outlook, giving a complete picture of the field. It is meant for a broad audience, from students to engineers and scientists, who are interested in the emerging world of plasma medical applications. It presents recent advances, primary challenges, and future directions of this exciting, cutting-edge field.

This book highlights information derived primarily from clinical samples, with particular reference to theoretical and scientific aspects of the human immune system. This text will focus on topics that range from host-pathogen interactions in infectious disease to host immune response in cancer, allergic diseases, neuroinflammatory diseases, and autoimmune disorders. The reader will also have a well-rounded understanding of the behavior of the immune system with particular emphasis on the role of immunoproteomics in immunotherapy, neuroprotective immunity for neurodegenerative and neuroinfectious disease, leukemia-associated dendritic cell induction of adaptive immunity dysregulation, and the role of immune checkpoint inhibitors in cancer, infection, as well as neuroinflammation. Taken together, the contents of this book are intended for both clinicians and researchers in academia and industry.

This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists.

This book is an introduction to cancer treatment, the basics of radio- and chemotherapy, drug actions, the eradication of cancer cells, and the origins and persistence of pharmacological and toxicological effects of drugs. It further provides ideas for research based on knowledge of cancer metastasis, invasive and molecular pathways, and diagnosis and treatment. Many of the adaptive features of cancer biology, clinical features, pathology and treatment are reviewed. In addition to introducing the major themes and theories, the book also advances the current discussion by moving beyond explanations for clinical implementation. Key Selling Features: Reviews basic cancer treatments Summarizes chemotherapies Discusses radiotherapies Examines pharmacological and toxicological approaches to treatment Introduces oncological drug development

Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use. Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.

The book presents a comprehensive and up-to-date overview of phytochemicals as efficient cancer therapeutics. Over the last few decades there has been a paradigm shift from conventional cancer therapeutic approaches to alternative and complementary medicinal approaches especially using phytoconstituents from natural products. As such, the book provides an in-depth understanding of phytochemicals targeting diverse signaling pathways involved in cancer along with the evaluation of the cancer modulatory effects of phytochemicals. It also highlights the potential modulatory effect of single nucleotide polymorphisms (SNPs) on the cancer-associated cellular pathways and their interactions with the phytochemicals. Further, it analyzes the drug delivery methods, bioavailability of active components of botanicals, and toxicity of phytochemicals. Lastly, the book elucidates the 3D cell culture and animal models systems to analyze the beneficial effects of phytochemicals in cancer.

Artificial Intelligence in Cancer: Diagnostic to Tailored Treatment provides theoretical concepts and practical techniques of AI and its applications in cancer management, building a roadmap on how to use AI in cancer at different stages of healthcare. It discusses topics such as the impactful role of AI during diagnosis and how it can support clinicians to make better decisions, AI tools to help pathologists identify exact types of cancer, how AI supports tumor profiling and can assist surgeons, and the gains in precision for oncologists using AI tools. Additionally, it provides information on AI used for survival and remission/recurrence analysis. The book is a valuable source for bioinformaticians, cancer researchers, oncologists, clinicians and members of the biomedical field who want to understand the promising field of AI applications in cancer management.

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease.